<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="b73013b5-ae70-40a9-bf0f-1a50abb987b1"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use FRINDOVYX safely and effectively. See full prescribing information for FRINDOVYX.<br/>
      <br/>FRINDOVYX<sup>TM</sup> (cyclophosphamide) injection, for intravenous use<br/>Initial U.S. Approval: 1959</title>
   <effectiveTime value="20250324"/>
   <setId root="5ad8ea65-4c98-487a-9c8d-df778765ec5e"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="128918748" root="1.3.6.1.4.1.519.1"/>
            <name>Avyxa Pharma, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="119187191" root="1.3.6.1.4.1.519.1"/>
                  <name>Avyxa Holdings, LLC.</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="20dde0da-d000-4888-b1b8-0f05cf9eee36"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250324"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="83831-119" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Frindovyx</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cyclophosphamide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator value="500" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="8N3DW7272P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYCLOPHOSPHAMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1XBF4E50HS" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>4-HYDROXYCYCLOPHOSPHAMIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="6UXW23996M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CYCLOPHOSPHAMIDE ANHYDROUS</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEHYDRATED ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, MULTI-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="83831-119-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250319"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210852" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250319"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="83831-120" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Frindovyx</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cyclophosphamide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator value="1" unit="g"/>
                              <denominator value="2" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="8N3DW7272P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYCLOPHOSPHAMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1XBF4E50HS" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>4-HYDROXYCYCLOPHOSPHAMIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="6UXW23996M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CYCLOPHOSPHAMIDE ANHYDROUS</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEHYDRATED ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="2" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, MULTI-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="83831-120-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250319"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210852" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250319"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="83831-121" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Frindovyx</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cyclophosphamide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator value="2" unit="g"/>
                              <denominator value="4" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="8N3DW7272P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYCLOPHOSPHAMIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1XBF4E50HS" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>4-HYDROXYCYCLOPHOSPHAMIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="6UXW23996M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CYCLOPHOSPHAMIDE ANHYDROUS</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEHYDRATED ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="4" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, MULTI-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="83831-121-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250319"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210852" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250319"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID130">
               <id root="e7fe39a0-6aa3-4706-aada-bc32d9b32d6d"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>RECENT MAJOR CHANGES</title>
               <effectiveTime value="20250129"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID132">Dosage and Administration (<linkHtml href="#ID8">2.2</linkHtml>, <linkHtml href="#ID10">2.3</linkHtml>)                                                                                 9/2024</paragraph>
                        <paragraph>Warnings and Precautions, Embryo Fetal Toxicity (<linkHtml href="#ID36">5.7</linkHtml>)                                                                           9/2024</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="99df7edf-c4a9-4d35-b6a8-30ceca287731"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID2">
                     <content styleCode="underline">Malignant Diseases</content>
                  </paragraph>
                  <paragraph>FRINDOVYX is indicated for the treatment of adult and pediatric patients with:</paragraph>
                  <list listType="unordered" ID="ID3" styleCode="Disc">
                     <item>malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma</item>
                     <item>multiple myeloma</item>
                     <item>leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration)</item>
                     <item>mycosis fungoides (advanced disease)</item>
                     <item>neuroblastoma (disseminated disease)</item>
                     <item>adenocarcinoma of the ovary</item>
                     <item>retinoblastoma</item>
                     <item>carcinoma of the breast</item>
                  </list>
                  <paragraph ID="ID4">Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs.</paragraph>
               </text>
               <effectiveTime value="20240926"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID101">FRINDOVYX is an alkylating drug indicated for treatment of adults and pediatric patients with:</paragraph>
                        <list listType="unordered" ID="ID102" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Malignant Diseases</content>: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma (<linkHtml href="#ID1">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID5">
               <id root="7205db06-09c4-4a82-8646-e8387d0ddd36"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250129"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID104">During or immediately after FRINDOVYX administration, administer adequate amounts of fluid to reduce the risk of urinary tract toxicity (<linkHtml href="#ID6">2.1</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Malignant Diseases: Adult and Pediatric Patients</content> (<linkHtml href="#ID8">2.2</linkHtml>)</paragraph>
                        <list listType="unordered" ID="ID105" styleCode="Disc">
                           <item>Intravenous: Initial course for patients with no hematologic deficiency: 40 mg/kg to 50 mg/ kg in divided doses over 2 to 5 days. Other regimens include 10 mg/kg to 15 mg/kg given every 7 to 10 days or 3 mg/kg to 5 mg/kg twice weekly. (<linkHtml href="#ID8">2.2</linkHtml>)</item>
                           <item>See full prescribing information for instructions on preparation, handling, and administration. (<linkHtml href="#ID8">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID6">
                     <id root="76cc1137-513a-4444-bf59-213a3fd442dd"/>
                     <title>2.1 Important Administration Instructions</title>
                     <text>
                        <paragraph ID="ID7">During or immediately after the administration of FRINDOVYX, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urinary tract toxicity. Therefore, FRINDOVYX should be administered in the morning.</paragraph>
                     </text>
                     <effectiveTime value="20240925"/>
                  </section>
               </component>
               <component>
                  <section ID="ID8">
                     <id root="b667ee29-eccb-45af-a7e0-c0e0f5787f4d"/>
                     <title>2.2 Recommended Dosage for Malignant Diseases</title>
                     <text>
                        <paragraph ID="ID9">
                           <content styleCode="underline">Adults and Pediatric Patients</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Intravenous</content>
                        </paragraph>
                        <paragraph>When used as the only oncolytic drug therapy, the recommended dosage for the initial course of FRINDOVYX for patients with no hematologic deficiency is 40 mg/kg to 50 mg/kg given intravenously in divided doses over a period of 2 to 5 days. Other intravenous regimens include 10 mg/kg to 15 mg/kg given every 7 to 10 days or 3 mg/kg to 5 mg/kg twice weekly.</paragraph>
                        <paragraph>Adjust the dosage of FRINDOVYX based on the specific regimen administered, response to treatment, myelosuppression or other adverse reactions, and patient risk factors <content styleCode="italics">[see <linkHtml href="#ID23">Warnings and Precautions (5)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240925"/>
                  </section>
               </component>
               <component>
                  <section ID="ID10">
                     <id root="28d41372-ea63-494f-9fe8-7e5a1f3a89a8"/>
                     <title>2.3 Preparation, Handling and Administration</title>
                     <text>
                        <paragraph ID="ID11">FRINDOVYX is a hazardous drug.<sup> </sup>Follow applicable special handling and disposal procedures<sup>1</sup>. Caution should be exercised when handling and preparing FRINDOVYX. To minimize the risk of dermal exposure, always wear gloves when handling vials containing FRINDOVYX.</paragraph>
                        <paragraph>
                           <content styleCode="underline">FRINDOVYX</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Intravenous Administration</content>
                        </paragraph>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use cyclophosphamide vials if there are signs of particulate matter.</paragraph>
                        <paragraph>Cyclophosphamide does not contain any antimicrobial preservative and thus care must be taken to assure the sterility of prepared solutions. Use aseptic technique.</paragraph>
                        <paragraph>
                           <content styleCode="italics">For Direct Intravenous Injection</content>
                        </paragraph>
                        <paragraph>Withdraw the prescribed dose of FRINDOVYX from the vial with a syringe and dilute with 0.9% Sodium Chloride Injection, USP to a concentration of 20 mg/mL of cyclophosphamide.</paragraph>
                        <paragraph>
                           <content styleCode="italics">For Intravenous Infusion</content>
                        </paragraph>
                        <paragraph>Withdraw the prescribed dose of FRINDOVYX from the vial with a syringe and dilute FRINDOVYX to a concentration of 2 mg/mL with any of the following diluents:  </paragraph>
                        <list listType="unordered" ID="ID133" styleCode="Disc">
                           <item>0.45% Sodium Chloride Injection, USP</item>
                           <item>5% Dextrose Injection, USP</item>
                           <item>5% Dextrose and 0.9% Sodium Chloride Injection, USP</item>
                        </list>
                        <paragraph ID="ID13">To reduce the likelihood of adverse reactions that appear to be administration rate-dependent (e.g., facial swelling, headache, nasal congestion, scalp burning), cyclophosphamide should be injected or infused very slowly. Duration of the infusion also should be appropriate for the volume and type of carrier fluid to be infused.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Storage of Diluted Cyclophosphamide Solution:</content>
                        </paragraph>
                        <paragraph>If not used immediately, for microbiological integrity, cyclophosphamide solutions should be stored as described in Table 1.</paragraph>
                        <table ID="ID14" width="44%" styleCode="Noautorules">
                           <caption>  Table 1: Storage of Cyclophosphamide Solutions </caption>
                           <col width="48%"/>
                           <col width="27%"/>
                           <col width="24%"/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="Lrule Toprule Botrule Rrule" align="left"> Diluent <br/>
                                 </td>
                                 <td colspan="2" styleCode=" Toprule Botrule Rrule" align="center"> Storage<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Rrule" align="center"> Room Temperature<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> Refrigerated<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Diluted Solution (20 mg/mL) for Direct Intravenous Injection</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> 0.9% Sodium Chloride Injection, USP <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> up to 24 hours<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> up to 6 days<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" valign="top" styleCode="Lrule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Diluted Solutions (2 mg/mL) for Intravenous Infusion </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> 0.45% Sodium Chloride Injection, USP <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> up to 24 hours<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> up to 6 days<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule Rrule" align="left"> 5% Dextrose Injection, USP <br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> up to 24 hours<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> up to 36 hours<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 5% Dextrose and 0.9% Sodium Chloride Injection, USP<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> up to 24 hours<br/>
                                 </td>
                                 <td styleCode=" Botrule Rrule" align="center"> up to 36 hours<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID17">
                           <content styleCode="bold">
                              <content styleCode="underline">Storage of Undiluted Cyclophosphamide Solution (Multiple-Dose Vial):</content>
                           </content>
                        </paragraph>
                        <paragraph>After first use, store partially used multiple-dose vial in the original carton refrigerated at 2°C to 8°C (36ºF to 46°F) for up to 28 days or at room temperature at 20°C to 25°C (68ºF to 77°F) for up to 7 days. Discard unused portion.</paragraph>
                     </text>
                     <effectiveTime value="20250129"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID18">
               <id root="7cf77e67-8a21-4ccf-a245-a2ecd2d8b761"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID19">FRINDOVYX: Clear, colorless or slight yellow, sterile solution of cyclophosphamide in multiple-dose vial in the following three strengths. </paragraph>
                  <list listType="unordered" ID="ID20" styleCode="Disc">
                     <item>500 mg/mL</item>
                     <item>1 g/2 mL (500 mg/mL)</item>
                     <item>2 g/4 mL (500 mg/mL)</item>
                  </list>
               </text>
               <effectiveTime value="20240927"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID107" styleCode="Disc">
                           <item>Injection: 500 mg/mL, 1 g/2 mL (500 mg/mL), and 2 g/4mL (500 mg/mL) in multiple-dose vial (<linkHtml href="#ID18">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID21">
               <id root="310b872b-2a6c-4bde-8054-d5610c29a94e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID22">
                     <content styleCode="underline">Hypersensitivity</content>
                  </paragraph>
                  <paragraph>FRINDOVYX is contraindicated in patients who have a history of severe hypersensitivity reactions to cyclophosphamide, any of its metabolites, or to other components of the product. Anaphylactic reactions including death have been reported with cyclophosphamide. Cross-sensitivity with other alkylating agents can occur.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Urinary Outflow Obstruction</content>
                  </paragraph>
                  <paragraph>FRINDOVYX is contraindicated in patients with urinary outflow obstruction <content styleCode="italics">[see <linkHtml href="#ID26">Warnings and Precautions (5.2)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250129"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID109" styleCode="Disc">
                           <item>Hypersensitivity to cyclophosphamide (<linkHtml href="#ID21">4</linkHtml>)</item>
                           <item>Urinary outflow obstruction (<linkHtml href="#ID21">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID23">
               <id root="dcdf6cfd-7929-45d8-a0fe-ef5f7bff2f5f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250129"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID111" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections</content>: Severe immunosuppression may lead to serious and sometimes fatal infections. Close hematological monitoring is required. (<linkHtml href="#ID24">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Urinary Tract and Renal Toxicity</content>: Hemorrhagic cystitis, pyelitis, ureteritis, and hematuria can occur. Urotoxicity can be fatal. Exclude or correct any urinary tract obstructions prior to treatment. (<linkHtml href="#ID26">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Cardiotoxicity</content>: Myocarditis, myopericarditis, pericardial effusion, arrhythmias and congestive heart failure, which may be fatal, have been reported. Monitor patients, especially those with risk factors for cardiotoxicity or pre-existing cardiac disease. (<linkHtml href="#ID28">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Pulmonary Toxicity</content>: Pneumonitis, pulmonary fibrosis and pulmonary veno-occlusive disease leading to respiratory failure may occur. Monitor patients for signs and symptoms of pulmonary toxicity. (<linkHtml href="#ID30">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Secondary malignancies</content>(<linkHtml href="#ID32">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Veno-occlusive Liver Diseas</content>e:  Fatal outcome can occur. (<linkHtml href="#ID34">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Alcohol content</content>: The alcohol content in a dose of FRINDOVYX may affect the central nervous system. This may include impairment of a patient's ability to drive or use machines immediately after infusion. (<linkHtml href="#ID36">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. Advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception. (<linkHtml href="#ID38">5.8</linkHtml>, <linkHtml href="#ID60">8.1</linkHtml>, <linkHtml href="#ID64">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID24">
                     <id root="91d166b0-398c-4667-996d-8d0d757f0537"/>
                     <title>5.1 Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections</title>
                     <text>
                        <paragraph ID="ID25">Cyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression which may lead to serious and sometimes fatal infections, including sepsis and septic shock. Latent infections can be reactivated <content styleCode="italics">[see <linkHtml href="#ID46">Adverse Reactions (6)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Antimicrobial prophylaxis may be indicated in certain cases of neutropenia at the discretion of the managing physician. In case of neutropenic fever, antibiotic therapy is indicated. Antimycotics and/or antivirals may also be indicated.</paragraph>
                        <paragraph>Monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed. Cyclophosphamide should not be administered to patients with neutrophils ≤1,500/mm<sup>3</sup> and platelets &lt; 50,000/mm<sup>3</sup>. Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection. G-CSF may be administered to reduce the risks of neutropenia complications associated with cyclophosphamide use. Primary and secondary prophylaxis with G-CSF should be considered in all patients considered to be at increased risk for neutropenia complications. The nadirs of the reduction in leukocyte count and thrombocyte count are usually reached in weeks 1 and 2 of treatment. Peripheral blood cell counts are expected to normalize after approximately 20 days. Bone marrow failure has been reported. Severe myelosuppression may be expected particularly in patients pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID26">
                     <id root="0b6ba432-ced3-44ba-a282-faa97f0f0765"/>
                     <title>5.2 Urinary Tract and Renal Toxicity</title>
                     <text>
                        <paragraph ID="ID27">Hemorrhagic cystitis, pyelitis, ureteritis, and hematuria have been reported with cyclophosphamide. Medical and/or surgical supportive treatment may be required to treat protracted cases of severe hemorrhagic cystitis. Discontinue cyclophosphamide therapy in case of severe hemorrhagic cystitis. </paragraph>
                        <paragraph>Urotoxicity (bladder ulceration, necrosis, fibrosis, contracture and secondary cancer) may require interruption of cyclophosphamide treatment or cystectomy. Urotoxicity can be fatal. Urotoxicity can occur with short-term or long-term use of cyclophosphamide.</paragraph>
                        <paragraph>Before starting treatment, exclude or correct any urinary tract obstructions <content styleCode="italics">[see <linkHtml href="#ID21">Contraindications (4)</linkHtml>]. </content>Urinary sediment should be checked regularly for the presence of erythrocytes and other signs of urotoxicity and/or nephrotoxicity. Cyclophosphamide should be used with caution, if at all, in patients with active urinary tract infections. Aggressive hydration with forced diuresis and frequent bladder emptying can reduce the frequency and severity of bladder toxicity. Mesna has been used to prevent severe bladder toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID28">
                     <id root="585c1dc8-a2c7-4643-a7bf-ef6213a3d523"/>
                     <title>5.3 Cardiotoxicity</title>
                     <text>
                        <paragraph ID="ID29">Myocarditis, myopericarditis, pericardial effusion including cardiac tamponade, and congestive heart failure, which may be fatal, have been reported with cyclophosphamide therapy.</paragraph>
                        <paragraph>Supraventricular arrhythmias (including atrial fibrillation and flutter) and ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported after treatment with regimens that included cyclophosphamide.</paragraph>
                        <paragraph>The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents.</paragraph>
                        <paragraph>Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with pre-existing cardiac disease.</paragraph>
                        <paragraph>Monitor patients with risk factors for cardiotoxicity and with pre-existing cardiac disease.</paragraph>
                     </text>
                     <effectiveTime value="20240927"/>
                  </section>
               </component>
               <component>
                  <section ID="ID30">
                     <id root="f2c51c52-1282-444b-9a8a-e4bee627f5c4"/>
                     <title>5.4 Pulmonary Toxicity</title>
                     <text>
                        <paragraph ID="ID31">Pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to respiratory failure have been reported during and following treatment with cyclophosphamide. Late onset pneumonitis (greater than 6 months after start of cyclophosphamide) appears to be associated with increased mortality. Pneumonitis may develop years after treatment with cyclophosphamide.</paragraph>
                        <paragraph>Monitor patients for signs and symptoms of pulmonary toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
               <component>
                  <section ID="ID32">
                     <id root="0ab63579-27dd-474b-b98b-53fd02049f7b"/>
                     <title>5.5 Secondary Malignancies</title>
                     <text>
                        <paragraph ID="ID33">Cyclophosphamide is genotoxic <content styleCode="italics">[see <linkHtml href="#ID89">Nonclinical Toxicology (13.1)</linkHtml>]</content>. Secondary malignancies (urinary tract cancer, myelodysplasia, acute leukemias, lymphomas, thyroid cancer, and sarcomas) have been reported in patients treated with cyclophosphamide-containing regimens<content styleCode="italics">. </content>The risk of bladder cancer may be reduced by prevention of hemorrhagic cystitis.</paragraph>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
               <component>
                  <section ID="ID34">
                     <id root="c7fc714b-1d92-417f-a7d4-d6c194bd189e"/>
                     <title>5.6 Veno-occlusive Liver Disease</title>
                     <text>
                        <paragraph ID="ID35">Veno-occlusive liver disease (VOD) including fatal outcome has been reported in patients receiving cyclophosphamide-containing regimens. A cytoreductive regimen in preparation for bone marrow transplantation that consists of cyclophosphamide in combination with whole-body irradiation, busulfan, or other agents has been identified as a major risk factor. VOD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide. Other risk factors predisposing to the development of VOD include preexisting disturbances of hepatic function, previous radiation therapy of the abdomen, and a low performance status.</paragraph>
                     </text>
                     <effectiveTime value="20250129"/>
                  </section>
               </component>
               <component>
                  <section ID="ID36">
                     <id root="d2c46702-7ccc-4bb4-ada0-98dfd89f9cf8"/>
                     <title>5.7 Alcohol Content</title>
                     <text>
                        <paragraph ID="ID37">The alcohol content in a dose of FRINDOVYX may affect the central nervous system and should be taken into account for patients in whom alcohol intake should be avoided or minimized. Consideration should be given to the alcohol content in FRINDOVYX on the ability to drive or use machines immediately after the infusion. </paragraph>
                        <paragraph>Each administration of FRINDOVYX at 50 mg per kg delivers 0.0448 g/kg of ethanol. For a 75 kg patient this would deliver 3.36 grams of ethanol <content styleCode="italics">[see <linkHtml href="#ID76">Description (11)</linkHtml>]</content>. Other cyclophosphamide products may have a different amount of alcohol or no alcohol.</paragraph>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
               <component>
                  <section ID="ID38">
                     <id root="eb713343-1864-4f45-9c36-2b2499b39a14"/>
                     <title>5.8 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph ID="ID39">Based on its mechanism of action and published reports of effects in pregnant patients or animals, FRINDOVYX can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#ID60">Use in Specific Populations (8.1),</linkHtml> </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID82">Clinical Pharmacology (12.1)</linkHtml>, and <linkHtml href="#ID89">Nonclinical Toxicology (13.1)</linkHtml>]</content>. Exposure to cyclophosphamide during pregnancy may cause birth defects, miscarriage, fetal growth retardation, and fetotoxic effects in the newborn. Cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monkeys.</paragraph>
                        <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to the fetus <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID60">Use in Specific Populations (8.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. Advise females of reproductive potential to use effective contraception during treatment with FRINDOVYX and for up to 1 year after completion of therapy. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with FRINDOVYX and for 4 months after completion of therapy <content styleCode="italics">[see <linkHtml href="#ID60">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#ID64">8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240925"/>
                  </section>
               </component>
               <component>
                  <section ID="ID40">
                     <id root="b17870f8-188a-4ff9-8250-1e022b1ed396"/>
                     <title>5.9 Infertility</title>
                     <text>
                        <paragraph ID="ID41">Male and female reproductive function and fertility may be impaired in patients being treated with FRINDOVYX. Cyclophosphamide interferes with oogenesis and spermatogenesis. It may cause sterility in both sexes. Development of sterility appears to depend on the dose of cyclophosphamide, duration of therapy, and the state of gonadal function at the time of treatment. Cyclophosphamide-induced sterility may be irreversible in some patients. Advise patients on the potential risks for infertility <content styleCode="italics">[see <linkHtml href="#ID64">Use in Specific Populations (8.3</linkHtml> and <linkHtml href="#ID66">8.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240925"/>
                  </section>
               </component>
               <component>
                  <section ID="ID42">
                     <id root="29dde4b6-bbb4-4737-8e46-8226ef23af0e"/>
                     <title>5.10 Impairment of Wound Healing</title>
                     <text>
                        <paragraph ID="ID43">Cyclophosphamide may interfere with normal wound healing.</paragraph>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
               <component>
                  <section ID="ID44">
                     <id root="b857d91f-c021-4bcc-be20-5c7449c08add"/>
                     <title>5.11 Hyponatremia</title>
                     <text>
                        <paragraph ID="ID45">Hyponatremia associated with increased total body water, acute water intoxication, and a syndrome resembling SIADH (syndrome of inappropriate secretion of antidiuretic hormone), which may be fatal, has been reported.</paragraph>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID46">
               <id root="13cb5094-e79f-4b9a-a019-782870800462"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID47">The following adverse reactions are discussed in more detail in other sections of the labeling.</paragraph>
                  <list listType="unordered" ID="ID48" styleCode="Disc">
                     <item>Hypersensitivity <content styleCode="italics">[see <linkHtml href="#ID21"> Contraindications (4)</linkHtml>]</content>
                     </item>
                     <item>Myelosuppression, Immunosuppression, Bone Marrow Failure, and Infections <content styleCode="italics">[see</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID24"> Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Urinary Tract and Renal Toxicity <content styleCode="italics">[see</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID26"> Warnings and Precautions (5.2)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>Cardiotoxicity <content styleCode="italics">[see <linkHtml href="#ID28"> Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Pulmonary Toxicity <content styleCode="italics">[see</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID30"> Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Secondary Malignancies <content styleCode="italics">[see</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID32"> Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Veno-occlusive Liver Disease <content styleCode="italics">[see</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID34"> Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>Alcohol Content <content styleCode="italics">[see <linkHtml href="#ID36"> Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Infertility <content styleCode="italics">[see <linkHtml href="#ID40"> Warnings and Precautions (5.9)</linkHtml> and <linkHtml href="#ID64">Use in Specific Populations (8.3</linkHtml> and <linkHtml href="#ID66">8.4)</linkHtml>]</content>
                     </item>
                     <item>Impaired Wound Healing <content styleCode="italics">[see</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID42"> Warnings and Precautions (5.10)]</linkHtml>
                        </content>
                     </item>
                     <item>Hyponatremia <content styleCode="italics">[see</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID44"> Warnings and Precautions (5.11)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240927"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID128">Adverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea. (<linkHtml href="#ID49">6.1</linkHtml>)</paragraph>
                        <paragraph ID="ID129">
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Avyxa Pharma, LLC at 1-888-520-0954 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID49">
                     <id root="c9089674-e667-46ac-b1ea-4ff54e9d4577"/>
                     <title>6.1 Clinical Trials and Postmarketing Experience</title>
                     <text>
                        <paragraph ID="ID50">The following adverse reactions associated with the use of cyclophosphamide were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>The most common adverse reactions were neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac: </content>cardiac arrest, ventricular fibrillation, ventricular tachycardia, cardiogenic shock, pericardial effusion (progressing to cardiac tamponade), myocardial hemorrhage, myocardial infarction, cardiac failure (including fatal outcomes), cardiomyopathy, myocarditis, pericarditis, carditis, atrial fibrillation, supraventricular arrhythmia, ventricular arrhythmia, bradycardia, tachycardia, palpitations, QT prolongation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Congenital, Familial and Genetic</content>: intra-uterine death, fetal malformation, fetal growth retardation, fetal toxicity (including myelosuppression, gastroenteritis).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Ear and Labyrinth: </content>deafness, hearing impaired, tinnitus.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine: </content>water intoxication.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye: </content>visual impairment, conjunctivitis, lacrimation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal: </content>gastrointestinal hemorrhage, acute pancreatitis, colitis, enteritis, cecitis, stomatitis, constipation, parotid gland inflammation, nausea, vomiting, diarrhea.</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administrative Site Conditions: </content>multiorgan failure, general physical deterioration, influenza-like illness, injection/infusion site reactions (thrombosis, necrosis, phlebitis, inflammation, pain, swelling, erythema), pyrexia, edema, chest pain, mucosal inflammation, asthenia, pain, chills, fatigue, malaise, headache, febrile neutropenia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hematologic: </content>myelosuppression, bone marrow failure, disseminated intravascular coagulation and hemolytic uremic syndrome (with thrombotic microangiopathy).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic: </content>veno-occlusive liver disease, cholestatic hepatitis, cytolytic hepatitis, hepatitis, cholestasis; hepatotoxicity with hepatic failure, hepatic encephalopathy, ascites, hepatomegaly, blood bilirubin increased, hepatic function abnormal, hepatic enzymes increased.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune: </content>immunosuppression, anaphylactic shock and hypersensitivity reaction.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections: </content>The following manifestations have been associated with myelosuppression and immunosuppression caused by cyclophosphamide: increased risk for and severity of pneumonias (including fatal outcomes), other bacterial, fungal, viral, protozoal and, parasitic infections; reactivation of latent infections, (including viral hepatitis, tuberculosis), <content styleCode="italics">Pneumocystis jiroveci</content>, herpes zoster, <content styleCode="italics">Strongyloides</content>, sepsis and septic shock.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations: </content>blood lactate dehydrogenase increased, C-reactive protein increased.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and Nutrition: </content>hyponatremia, fluid retention, blood glucose increased, blood glucose decreased.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and Connective Tissue</content>: rhabdomyolysis, scleroderma, muscle spasms, myalgia, arthralgia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Neoplasms: </content>acute leukemia, myelodysplastic syndrome, lymphoma, sarcomas, renal cell carcinoma, renal pelvis cancer, bladder cancer, ureteric cancer, thyroid cancer.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System: </content>encephalopathy, convulsion, dizziness, neurotoxicity has been reported and manifested as reversible posterior leukoencephalopathy syndrome, myelopathy, peripheral neuropathy, polyneuropathy, neuralgia, dysesthesia, hypoesthesia, paresthesia, tremor, dysgeusia, hypogeusia, parosmia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pregnancy: </content>premature labor.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric: </content>confusional state.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and Urinary: </content>renal failure, renal tubular disorder, renal impairment, nephropathy toxic, hemorrhagic cystitis, bladder necrosis, cystitis ulcerative, bladder contracture, hematuria, nephrogenic diabetes insipidus, atypical urinary bladder epithelial cells.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Reproductive System: </content>infertility, ovarian failure, ovarian disorder, amenorrhea, oligomenorrhea, testicular atrophy, azoospermia, oligospermia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory: </content>pulmonary veno-occlusive disease, acute respiratory distress syndrome, interstitial lung disease as manifested by respiratory failure (including fatal outcomes), obliterative bronchiolitis, organizing pneumonia, alveolitis allergic, pneumonitis, pulmonary hemorrhage; respiratory distress, pulmonary hypertension, pulmonary edema, pleural effusion, bronchospasm, dyspnea, hypoxia, cough, nasal congestion, nasal discomfort, oropharyngeal pain, rhinorrhea.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue: </content>toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, palmar-plantar erythrodysesthesia syndrome, radiation recall dermatitis, toxic skin eruption, urticaria, dermatitis, blister, pruritus, erythema, nail disorder, facial swelling, hyperhidrosis, alopecia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Tumor lysis syndrome<content styleCode="bold">: </content>
                           </content>like other cytotoxic drugs, cyclophosphamide may induce tumor-lysis syndrome and hyperuricemia in patients with rapidly growing tumors.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular: </content>pulmonary embolism, venous thrombosis, vasculitis, peripheral ischemia, hypertension, hypotension, flushing, hot flush.</paragraph>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID51">
               <id root="b24169f2-8b84-4b4c-b018-2aa6d75625b1"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250129"/>
               <component>
                  <section ID="ID52">
                     <id root="cf9c347f-0494-4442-a64e-7020721feafd"/>
                     <title>7.1 Effect of Other Drugs on Cyclophosphamide Exposure</title>
                     <text>
                        <paragraph ID="ID53">
                           <content styleCode="underline">Protease Inhibitors</content>
                        </paragraph>
                        <paragraph>Concomitant use of protease inhibitors may increase the concentration of cytotoxic metabolites and may enhance the toxicities of cyclophosphamide, including higher incidence of infections, neutropenia, and mucositis. Monitor for increased toxicities in patients receiving protease inhibitors.</paragraph>
                     </text>
                     <effectiveTime value="20240927"/>
                  </section>
               </component>
               <component>
                  <section ID="ID54">
                     <id root="c5cd4a4b-5a3e-4c0b-a140-3fe5da94d3d2"/>
                     <title>7.2 Drugs that Potentiate Cyclophosphamide Toxicities</title>
                     <text>
                        <paragraph ID="ID55">Drugs or agents with similar toxicities to FRINDOVYX and can potentiate these effects are listed in Table 2.</paragraph>
                        <table ID="ID56" width="707" styleCode="Noautorules">
                           <caption>  Table 2: Drugs that Potentiate Cyclophosphamide Toxicities </caption>
                           <col width="173"/>
                           <col width="534"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Toxicity</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Drugs</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Increased hematotoxicity and/or immunosuppression<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●     ACE inhibitors: ACE inhibitors can cause leukopenia.<br/> ●     Natalizumab<br/> ●     Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide     was administered after paclitaxel infusion.<br/> ●     Thiazide diuretics<br/> ●     Zidovudine<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Increased cardiotoxicity<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●     Anthracyclines<br/> ●     Cytarabine<br/> ●     Pentostatin<br/> ●     Radiation therapy of the cardiac region<br/> ●     Trastuzumab<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Increased pulmonary toxicity<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●     Amiodarone<br/> ●     G-CSF, GM-CSF (granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Increased nephrotoxicity<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●     Amphotericin B<br/> ●     Indomethacin: Acute water intoxication has been reported with concomitant use of indomethacin<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Increase in other toxicities:<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●     Azathioprine: Increased risk of hepatotoxicity (liver necrosis)<br/> ●     Busulfan: Increased incidence of hepatic veno-occlusive disease and mucositis has been reported.<br/> ●     Protease inhibitors: Increased incidence of mucositis<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Increased risk of hemorrhagic cystitis<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> ●     Radiation treatment: Increased risk of hemorrhagic cystitis may result from a combined effect of cyclophosphamide and past or concomitant radiation treatment.<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
               <component>
                  <section ID="ID57">
                     <id root="d5be87f6-5965-446a-8995-6362075b7791"/>
                     <title>7.3 Effect of Cyclophosphamide on Other Drugs</title>
                     <text>
                        <paragraph ID="ID58">
                           <content styleCode="underline">Metronidazole</content>
                        </paragraph>
                        <paragraph>Acute encephalopathy has been reported in a patient receiving cyclophosphamide and metronidazole. Monitor for neurologic toxicities in patients receiving metronidazole.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Tamoxifen</content>
                        </paragraph>
                        <paragraph>Concomitant use of tamoxifen and a cyclophosphamide-containing chemotherapy regimen may increase the risk of thromboembolic complications. Monitor for signs and symptoms of thromboembolic events in patients receiving tamoxifen.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Coumarins</content>
                        </paragraph>
                        <paragraph>Both increased and decreased warfarin effect have been reported in patients receiving warfarin and cyclophosphamide. Monitor anticoagulant activity closely in patients receiving warfarin or other coumarins.</paragraph>
                        <paragraph>            </paragraph>
                        <paragraph>
                           <content styleCode="underline">Cyclosporine</content>
                        </paragraph>
                        <paragraph>Concomitant administration of cyclophosphamide may decrease serum concentrations of cyclosporine. This interaction may result in an increased incidence of graft-versus-host disease. Monitor for signs and symptoms of graft-versus-host disease in patients receiving cyclosporine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Depolarizing Muscle Relaxants</content>
                        </paragraph>
                        <paragraph>If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, alert the anesthesiologist.</paragraph>
                        <paragraph>Cyclophosphamide causes a marked and persistent inhibition of cholinesterase activity. Prolonged apnea may occur with concurrent depolarizing muscle relaxants (e.g., succinylcholine). </paragraph>
                     </text>
                     <effectiveTime value="20250129"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID59">
               <id root="7fa4b629-d8a4-4d1c-9c5b-c39a034f4eb4"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240927"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID116" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Lactation</content>: Advise not to breastfeed. (<linkHtml href="#ID62">8.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Renal Impairment</content>: Monitor for toxicity in patients with moderate and severe renal impairment. (<linkHtml href="#ID70">8.6</linkHtml>, <linkHtml href="#ID86">12.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID60">
                     <id root="6da48535-cfe8-4201-bfd9-7a4a351d5d6a"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID61">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Based on its mechanism of action and published reports of effects in pregnant patients or animals, FRINDOVYX can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#ID82">Clinical Pharmacology (12.1)</linkHtml> and <linkHtml href="#ID89">Nonclinical Toxicology (13.1)</linkHtml>]</content>. Exposure to cyclophosphamide during pregnancy may cause fetal malformations, miscarriage, fetal growth retardation, and toxic effects in the newborn <content styleCode="italics">[see Data]</content>. Cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monkeys <content styleCode="italics">[see Data]</content>. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects is 2% - 4% and of miscarriage is 15% - 20% of clinically recognized pregnancies.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>Malformations of the skeleton, palate, limbs and eyes as well as miscarriage have been reported after exposure to cyclophosphamide in the first trimester. Fetal growth retardation and toxic effects manifesting in the newborn, including leukopenia, anemia, pancytopenia, severe bone marrow hypoplasia, and gastroenteritis have been reported after exposure to cyclophosphamide.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Administration of cyclophosphamide to pregnant mice, rats, rabbits and monkeys during the period of organogenesis at doses at or below the dose in patients based on body surface area resulted in various malformations, which included neural tube defects, limb and digit defects and other skeletal anomalies, cleft lip and palate, and reduced skeletal ossification.</paragraph>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
               <component>
                  <section ID="ID62">
                     <id root="da30430b-66bc-4aa7-a144-ff0b9c10a9f0"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID63">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Cyclophosphamide is present in breast milk. Neutropenia, thrombocytopenia, low hemoglobin, and diarrhea have been reported in infants breast fed by women treated with cyclophosphamide. Because of the potential for serious adverse reactions in a breastfed child, advise lactating women not to breastfeed during treatment with FRINDOVYX and for 1 week after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
               <component>
                  <section ID="ID64">
                     <id root="cbe9b7a2-d61c-4968-80f3-8b78a4768d76"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph ID="ID65">FRINDOVYX can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#ID60">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Verify the pregnancy status of females of reproductive potential prior to the initiation of FRINDOVYX <content styleCode="italics">[see <linkHtml href="#ID60">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraception during treatment with FRINDOVYX and for up to 1 year after completion of therapy.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Based on findings in genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception during treatment with FRINDOVYX and for 4 months after completion of therapy <content styleCode="italics">[see <linkHtml href="#ID89">Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Amenorrhea, transient or permanent, associated with decreased estrogen and increased gonadotropin secretion develops in a proportion of women treated with cyclophosphamide. Affected patients generally resume regular menses within a few months after cessation of therapy. The risk of premature menopause with cyclophosphamide increases with age. Oligomenorrhea has also been reported in association with cyclophosphamide treatment.</paragraph>
                        <paragraph>Animal data suggest an increased risk of failed pregnancy and malformations may persist after discontinuation of cyclophosphamide as long as oocytes/follicles exist that were exposed to cyclophosphamide during any of their maturation phases. The exact duration of follicular development in humans is not known, but may be longer than 12 months <content styleCode="italics">[see <linkHtml href="#ID89">Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Men treated with cyclophosphamide may develop oligospermia or azoospermia which are normally associated with increased gonadotropin but normal testosterone secretion.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID66">
                     <id root="4e4aa16b-322d-4514-8e80-cbe966aec5c8"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID67">The safety and effectiveness of FRINDOVYX have been established in pediatric patients and information on this use is discussed throughout the labeling.</paragraph>
                        <paragraph>The alcohol content of FRINDOVYX should be taken into account when given to pediatric patients <content styleCode="italics">[see <linkHtml href="#ID36">Warnings and Precautions (5.7)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Pre-pubescent females who receive cyclophosphamide generally develop secondary sexual characteristics normally and have regular menses. Ovarian fibrosis with apparently complete loss of germ cells after prolonged administration of cyclophosphamide in late pre-pubescence has been reported. Females who received cyclophosphamide who have retained ovarian function after completing treatment are at increased risk of developing premature menopause.</paragraph>
                        <paragraph>Pre-pubescent males who receive cyclophosphamide develop secondary sexual characteristics normally, but may have oligospermia or azoospermia and increased gonadotropin secretion. Some degree of testicular atrophy may occur. Cyclophosphamide-induced azoospermia is reversible in some patients, though the reversibility may not occur for several years after cessation of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20240927"/>
                  </section>
               </component>
               <component>
                  <section ID="ID68">
                     <id root="160f1e9c-3287-4a4d-814e-420a4bbb20af"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID69">There is insufficient data from clinical studies of cyclophosphamide available for patients 65 years of age and older to determine whether they respond differently than younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac functioning, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
               <component>
                  <section ID="ID70">
                     <id root="c80687c6-0497-45ca-a79b-8acf3b0411b4"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID71">In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites which may increase toxicity <content styleCode="italics">[see <linkHtml href="#ID86">Clinical Pharmacology (12.3)</linkHtml>]</content>. Monitor patients with severe renal impairment (CLcr =10 mL/min to 24 mL/min) for signs and symptoms of toxicity.</paragraph>
                        <paragraph>Cyclophosphamide and its metabolites are dialyzable although there are probably quantitative differences depending upon the dialysis system. In patients requiring dialysis, consider using a consistent interval between cyclophosphamide administration and dialysis.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="ID72">
                     <id root="0ca2c4ad-8353-485d-b41c-f2e958974fe6"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID73">Patients with severe hepatic impairment have reduced conversion of cyclophosphamide to the active 4-hydroxyl metabolite, potentially reducing efficacy <content styleCode="italics">[see <linkHtml href="#ID86">Clinical Pharmacology (12.3)</linkHtml>]</content>. Monitor patients with severe hepatic impairment (total bilirubin &gt; 3 x ULN and any aspartate aminotransferase (AST)) for reduced effectiveness of cyclophosphamide.</paragraph>
                        <paragraph>The alcohol content of FRINDOVYX should be taken into account when given to patients with hepatic impairment <content styleCode="italics">[see <linkHtml href="#ID36">Warnings and Precautions (5.7)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240925"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID74">
               <id root="a2a151b6-5062-49d8-95ed-307ca292e161"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID75">No specific antidote for cyclophosphamide is known.</paragraph>
                  <paragraph>Overdosage should be managed with supportive measures, including appropriate treatment for any concurrent infection, myelosuppression, or cardiac toxicity should it occur.</paragraph>
                  <paragraph>Serious consequences of overdosage include manifestations of dose dependent toxicities such as myelosuppression, urotoxicity, cardiotoxicity (including cardiac failure), veno-occlusive hepatic disease, and stomatitis <content styleCode="italics">[see <linkHtml href="#ID24">Warnings and Precautions (5.1,</linkHtml> <linkHtml href="#ID26">5.2</linkHtml>, <linkHtml href="#ID28">5.3</linkHtml>, and <linkHtml href="#ID34">5.6)</linkHtml>]</content>.</paragraph>
                  <paragraph>Patients who received an overdose should be closely monitored for the development of toxicities, and hematologic toxicity in particular.</paragraph>
                  <paragraph>Cyclophosphamide and its metabolites are dialyzable. Therefore, rapid hemodialysis is indicated when treating any suicidal or accidental overdose or intoxication <content styleCode="italics">[see <linkHtml href="#ID86">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                  <paragraph>Cystitis prophylaxis with mesna may be helpful in preventing or limiting urotoxic effects with cyclophosphamide overdose.</paragraph>
               </text>
               <effectiveTime value="20240925"/>
            </section>
         </component>
         <component>
            <section ID="ID76">
               <id root="72fa51cb-8bf3-4639-a401-cdadc872d7cb"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID77">Cyclophosphamide is an alkylating drug. It is an antineoplastic drug chemically related to the nitrogen mustards. The chemical name for cyclophosphamide is (±)-2-[Bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, and has the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID79">Cyclophosphamide is a white crystalline powder with the molecular formula C<sub>7</sub>H<sub>15</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub> P•H<sub>2</sub>O and a molecular weight of 279.1. Cyclophosphamide is soluble in water, saline, or ethanol. The pK<sub>a</sub> of cyclophosphamide is 5.7. </paragraph>
                  <paragraph>FRINDOVYX is a clear, colorless to slight yellow sterile solution available as 500 mg/mL, 1 g/2 mL, and 2 g/4 mL in multiple dose vial for dilution prior to intravenous administration.</paragraph>
                  <list listType="unordered" ID="ID80" styleCode="Disc">
                     <item>500 mg/mL vial contains 534.5 mg cyclophosphamide monohydrate, equivalent to 500 mg cyclophosphamide and 500 mg dehydrated alcohol (equivalent to 63% v/v).</item>
                     <item>1 g/2 mL vial contains 1069.0 mg cyclophosphamide monohydrate equivalent to 1 g cyclophosphamide and 1000 mg dehydrated alcohol (equivalent to 63% v/v).</item>
                     <item>2 g/4 mL vial contains 2138.0 mg cyclophosphamide monohydrate, equivalent to 2 g cyclophosphamide and 2000 mg dehydrated alcohol (equivalent to 63% v/v).</item>
                  </list>
               </text>
               <effectiveTime value="20250129"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="8b6290e7-533f-4b49-8f00-a84e22abfb35-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID81">
               <id root="aef10e92-c52a-4a2e-9b70-f09f37fa6410"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240925"/>
               <component>
                  <section ID="ID82">
                     <id root="1ace4808-543e-4325-be48-c22795c82545"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID83">The mechanism of action has not been fully characterized. However, cross-linking of tumor cell DNA may be involved.</paragraph>
                        <paragraph>The active alkylating metabolites of cyclophosphamide interfere with the growth of susceptible rapidly proliferating malignant cells.</paragraph>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
               <component>
                  <section ID="ID84">
                     <id root="ff5e40c7-b9fb-408b-b0dd-6469b205223b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID85">Cyclophosphamide exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized.</paragraph>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
               <component>
                  <section ID="ID86">
                     <id root="3e10e222-2d2a-4767-a047-678d144340ba"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID87">Cyclophosphamide is a prodrug. Cyclophosphamide pharmacokinetics are linear over the approved recommended dose range.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The volume of distribution of cyclophosphamide is 30 to 50 L. Cyclophosphamide is approximately 20% protein bound, with no dose dependent changes.  Some metabolites are greater than 60% protein bound.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The elimination half-life (t½) of cyclophosphamide ranges from 3 to 12 hours, and the clearance (CL) ranges from 4 to 5.6 L/h.</paragraph>
                        <paragraph>When cyclophosphamide was administered at 4 g/m<sup>2</sup> (approximately 2 times the approved recommended dosage) over a 90-minutes infusion, concentration-time data demonstrate saturable elimination in parallel with first-order renal elimination.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Cyclophosphamide is metabolized by cytochrome P450s including CYP2A6, 2B6, 3A, 2C9, and 2C19. Cyclophosphamide is activated to form 4-hydroxycyclophosphamide, which is in equilibrium with its ring-open tautomer aldophosphamide. 4-hydroxycyclophosphamide and aldophosphamide can undergo oxidation by aldehyde dehydrogenases to form the inactive metabolites 4-ketocyclophosphamide and carboxyphosphamide, respectively. Aldophosphamide can undergo β-elimination to form active metabolites phosphoramide mustard and acrolein. This spontaneous conversion can be catalyzed by albumin and other proteins. At high doses, the fraction of parent compound cleared by 4-hydroxylation is reduced resulting in non-linear elimination of cyclophosphamide. </paragraph>
                        <paragraph>Cyclophosphamide appears to induce its own metabolism. This auto-induction results in an increase in CL, increased formation of active 4-hydroxycyclophosphamide and shortened t½ following multiple doses administered at 12-to 24-hour interval.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Cyclophosphamide and its metabolites are eliminated by hepatic and renal pathways. Cyclophosphamide is primarily excreted as metabolites. Ten to 20% is excreted unchanged in the urine. A small percentage of cyclophosphamide may be eliminated unchanged in bile.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment</content>
                        </paragraph>
                        <paragraph>Following one-hour intravenous infusion, cyclophosphamide AUC increased by 38% in patients with CLcr of 25 to 50 mL/min, by 77% in patients with CLcr of 10 to 24 mL/min and by 23% in the hemodialysis group (CLcr of &lt; 10 mL/min) compared to the control group (CLcr≥ 80 mL/min). </paragraph>
                        <paragraph>Cyclophosphamide is dialyzable. Dialysis clearance averaged 104 mL/min, which is similar to the metabolic clearance of 95 mL/min for cyclophosphamide. A mean of 37% of the administered dose of cyclophosphamide was removed during a 4-hour hemodialysis period. The t½ was 3.3 hours in patients during hemodialysis, a 49% reduction compared to t½ of  6.5 hours  in uremic patients. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>Cyclophosphamide CL is decreased by 40% (45 ± 8.6 L/kg) and t½ is prolonged by 64% (12.5 ± 1 hours) in patients with hepatic impairment with a mean bilirubin 3.5 mg/dL and mean AST 90 IU/L compared to patients with normal hepatic function (mean bilirubin 0.5 mg/dL, mean AST 10 IU/L). </paragraph>
                     </text>
                     <effectiveTime value="20240925"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID88">
               <id root="6eef57e3-68b9-480f-8dff-81efc1e376c5"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20240718"/>
               <component>
                  <section ID="ID89">
                     <id root="13c12286-0fcb-4087-a2a1-80bc9cc76d60"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID90">Cyclophosphamide administered by different routes, including intravenous, subcutaneous or intraperitoneal injection, or in drinking water, caused tumors in both mice and rats. In addition to leukemia and lymphoma, benign and malignant tumors were found at various tissue sites, including urinary bladder, mammary gland, lung, liver, and injection site <content styleCode="italics">[see <linkHtml href="#ID32">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                        <paragraph>Cyclophosphamide was mutagenic and clastogenic in multiple <content styleCode="italics">in vitro </content>and <content styleCode="italics">in vivo </content>genetic toxicology studies.</paragraph>
                        <paragraph>Cyclophosphamide is genotoxic in male and female germ cells. Animal data indicate that exposure of oocytes to cyclophosphamide during follicular development may result in a decreased rate of implantations and viable pregnancies, and in an increased risk of malformations. Male mice and rats treated with cyclophosphamide show alterations in male reproductive organs (e.g., decreased weights, atrophy, changes in spermatogenesis), and decreases in reproductive potential (e.g., decreased implantations and increased post-implantation loss) and increases in fetal malformations when mated with untreated females <content styleCode="italics">[see <linkHtml href="#ID64">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240718"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID91">
               <id root="22cf3f4f-b72d-4a1b-88a8-5bbfc9113635"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <list listType="ordered" ID="ID92">
                     <item> OSHA Hazardous Drugs. <content styleCode="italics">OSHA.</content> http://www.osha.gov/SLTC/hazardousdrugs/index.html.</item>
                  </list>
               </text>
               <effectiveTime value="20240718"/>
            </section>
         </component>
         <component>
            <section ID="ID93">
               <id root="884d4b13-80e4-49b1-bc9e-4b5a14f22342"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID94">FRINDOVYX<sup>TM</sup> is a ready-to-dilute clear, colorless to slight yellow sterile solution containing cyclophosphamide and is supplied in multiple-dose vial. </paragraph>
                  <paragraph>
                     <content styleCode="underline">FRINDOVYX<sup>TM</sup> Injection</content>
                  </paragraph>
                  <table ID="ID95" width="606" styleCode="Noautorules">
                     <caption/>
                     <col width="202"/>
                     <col width="158"/>
                     <col width="246"/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> NDC Number</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Strength</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Vial Presentation</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 83831-119-01<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> 500 mg/mL<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Multiple-dose vial, carton of 1<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 83831-120-02<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> 1 g/2 mL<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Multiple-dose vial, carton of 1<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> 83831-121-04<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> 2 g/4 mL<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="left"> Multiple-dose vial, carton of 1<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID96">Store vials refrigerated at 2°C to 8°C (36°F to 46°F).</paragraph>
                  <paragraph>Store diluted solutions of cyclophosphamide according to Table 1 <content styleCode="italics">[see <linkHtml href="#ID10">Dosage and Administration (2.3)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>Cyclophosphamide is a hazardous product. Follow special handling and disposal procedures.<sup>1</sup>
                  </paragraph>
               </text>
               <effectiveTime value="20250129"/>
            </section>
         </component>
         <component>
            <section ID="ID124">
               <id root="669b632b-d857-48a3-8e94-c4530e5eb07d"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID125">Advise the patient of the following: </paragraph>
                  <paragraph>
                     <content styleCode="underline">Myelosuppression, Immunosuppression, and Infections</content>
                  </paragraph>
                  <paragraph>●      Inform patients of the possibility of myelosuppression, immunosuppression, and infections (sometimes fatal). Explain the need for routine blood cell counts. Instruct patients to monitor their temperature frequently and immediately report any occurrence of fever <content styleCode="italics">[see <linkHtml href="#ID24">Warnings and Precautions (5.1)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Urinary Tract and Renal Toxicity</content>
                  </paragraph>
                  <paragraph>●      Advise the patient to report urinary symptoms (patients should report if their urine has turned a pink or red color) and the need for increasing fluid intake and frequent voiding <content styleCode="italics">[see <linkHtml href="#ID26">Warnings and Precautions (5.2)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Cardiotoxicity</content>
                  </paragraph>
                  <paragraph>●      Inform patients of the possibility of cardiotoxicity (which may be fatal).</paragraph>
                  <paragraph>●      Advise patients to contact a health care professional immediately for any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness <content styleCode="italics">[see <linkHtml href="#ID28">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pulmonary Toxicity</content>
                  </paragraph>
                  <paragraph>●      Warn patients of the possibility of developing non-infectious pneumonitis. Advise patients to report promptly any new or worsening respiratory symptoms <content styleCode="italics">[see <linkHtml href="#ID30">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Secondary Malignancies</content>
                  </paragraph>
                  <paragraph>●      Inform patients that there is an increased risk of secondary malignancies with FRINDOVYX <content styleCode="italics">[see <linkHtml href="#ID32">Warnings and Precautions (5.5)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Alcohol Content</content>
                  </paragraph>
                  <paragraph>●      Explain to patients the possible effects of the alcohol content in FRINDOVYX, including possible effects on the central nervous system. Patients in whom alcohol should be avoided or minimized should consider the alcohol content of FRINDOVYX. Alcohol could impair their ability to drive or use machines immediately after infusion <content styleCode="italics">[see <linkHtml href="#ID36">Warnings and Precautions (5.7)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>●      Inform female patients of the risk to a fetus and potential loss of pregnancy.  Advise females to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see <linkHtml href="#ID38">Warnings and Precautions (5.8)</linkHtml> </content>and <content styleCode="italics">
                        <linkHtml href="#ID60">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>●      Advise female patients of reproductive potential to use effective contraception during treatment and for up to 1 year after completion of therapy <content styleCode="italics">[see <linkHtml href="#ID38">Warnings and Precautions (5.8)</linkHtml> </content>and <content styleCode="italics">
                        <linkHtml href="#ID60">Use in Specific Populations (8.1, </linkHtml>
                        <linkHtml href="#ID64">8.3)</linkHtml>]</content>. </paragraph>
                  <paragraph>●      Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 4 months after completion of therapy <content styleCode="italics">[see <linkHtml href="#ID38">Warnings and Precautions (5.8) </linkHtml>
                     </content>and <content styleCode="italics">
                        <linkHtml href="#ID60">Use in Specific Populations (8.1,</linkHtml> <linkHtml href="#ID64">8.3)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>●      Advise lactating women not to breastfeed during treatment and for 1 week after the last dose of FRINDOVYX <content styleCode="italics">[see <linkHtml href="#ID62">Use in Specific Populations (8.2)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Infertility</content>
                  </paragraph>
                  <paragraph>●      Advise males and females of reproductive potential that FRINDOVYX may impair fertility <content styleCode="italics">[see <linkHtml href="#ID40">Warnings and Precautions (5.9)</linkHtml> and <linkHtml href="#ID64">Use in Specific Populations (8.3,</linkHtml> <linkHtml href="#ID66">8.4)</linkHtml>]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Common Adverse Reactions</content>
                  </paragraph>
                  <paragraph>●      Explain to patients that side effects such as nausea, vomiting, stomatitis, impaired wound healing, amenorrhea, premature menopause, sterility and hair loss may be associated with cyclophosphamide administration. Other undesirable effects (including, e.g., dizziness, blurred vision, visual impairment) could affect the ability to drive or use machines <content styleCode="italics">[see <linkHtml href="#ID49">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hydration and Important Administration Instructions</content>
                  </paragraph>
                  <paragraph>●      Advise the patients that during or immediately after the administration, adequate amounts of fluid are required to reduce the risk of urinary tract toxicity <content styleCode="italics">[see <linkHtml href="#ID6">Dosage and Administration (2.1)</linkHtml>].</content>
                  </paragraph>
                  <table ID="ID126" width="708" styleCode="Noautorules">
                     <caption/>
                     <col width="223"/>
                     <col width="485"/>
                     <tbody>
                        <tr>
                           <td valign="top" align="left">
                              <content styleCode="bold"> Manufactured for:</content>
                              <br/> Avyxa Pharma, LLC<br/> New Jersey 07054, USA<br/> Made in India<br/>
                           </td>
                           <td valign="top" align="right">
                              <renderMultiMedia referencedObject="IMGID1261"/>
                              <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250129"/>
               <component>
                  <observationMedia ID="IMGID1261">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="8b6290e7-533f-4b49-8f00-a84e22abfb35-126-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID117">
               <id root="45a95337-1da1-4f28-83e3-8366d3671659"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <renderMultiMedia referencedObject="MM2">
                     <caption>Frindovyx (cyclophosphamide) Injection, 500mg/mL - Vial Label</caption>
                  </renderMultiMedia>
                  <renderMultiMedia referencedObject="MM3">
                     <caption>Frindovyx (cyclophosphamide) Injection, 500 mg/ mL - Carton Label</caption>
                  </renderMultiMedia>
                  <renderMultiMedia referencedObject="MM4">
                     <caption>Frindovyx (cyclophosphamide) Injection, 1 g/2 mL - Vial Label</caption>
                  </renderMultiMedia>
                  <renderMultiMedia referencedObject="MM5"/>
                  <renderMultiMedia referencedObject="MM6">
                     <caption>Frindovyx (cyclophosphamide) Injection, 2 g/4 mL - Vial Label</caption>
                  </renderMultiMedia>
                  <renderMultiMedia referencedObject="MM7">
                     <caption>Frindovyx (cyclophosphamide) Injection, 2 g/ 4 mL - Carton Label</caption>
                  </renderMultiMedia>
               </text>
               <effectiveTime value="20250129"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Frindovyx (cyclophosphamide) Injection, 500mg/mL - Vial Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="8b6290e7-533f-4b49-8f00-a84e22abfb35-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Frindovyx (cyclophosphamide) Injection, 500 mg/ mL - Carton Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="8b6290e7-533f-4b49-8f00-a84e22abfb35-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Frindovyx (cyclophosphamide) Injection, 1 g/2 mL - Vial Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="8b6290e7-533f-4b49-8f00-a84e22abfb35-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Frindovyx (cyclophosphamide) Injection, 1 g/2  mL - Carton Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="8b6290e7-533f-4b49-8f00-a84e22abfb35-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Frindovyx (cyclophosphamide) Injection, 2 g/4 mL - Vial Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="8b6290e7-533f-4b49-8f00-a84e22abfb35-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Frindovyx (cyclophosphamide) Injection, 2 g/ 4 mL - Carton Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="8b6290e7-533f-4b49-8f00-a84e22abfb35-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>